- The 8th Biennial Meeting of the Asian Society of Gynecologic Oncology, December 1st to 3rd, 2023
-
Hsu HC, Kim JW, Park JY, Suh DH, Kim SI, Chen JR, Wang PH
- KMID: 2564889
- J Gynecol Oncol.
- 2024 Mar;35(2):e67.
- doi: 10.3802/jgo.2024.35.e67
-
- CITED
-
- Close
- SHARE
-
- Close
- Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
-
Shim SH, Lee JY, Lee YY, Park JY, Lee YJ, Kim SI, Han GH, Yang EJ, Noh JJ, Yim GW, Son JH, Kim NK, Kim TH, Kong TW, Choi YJ, Cho A, Lim H, Jang EB, Cho HW, Suh DH
- KMID: 2564888
- J Gynecol Oncol.
- 2024 Mar;35(2):e66.
- doi: 10.3802/jgo.2024.35.e66
In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines
-
Yoo JG, Lee SJ, Nam EJ, No JH, Park JY, Song JY, Shin SJ, Yun BS, Park ST, Lee SH, Suh DH, Kim YB, Lee TS, Bae JM, Lee KH
- KMID: 2564882
- J Gynecol Oncol.
- 2024 Mar;35(2):e44.
- doi: 10.3802/jgo.2024.35.e44
This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on... -
- CITED
-
- Close
- SHARE
-
- Close
- Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement
-
Kim JH, Kim DY, Kim J, Noh JJ, Hwang WY, Baek MH, Choi MC, Joo WD, Lee YJ, Suh DH, Kim YB
- KMID: 2564883
- J Gynecol Oncol.
- 2024 Mar;35(2):e45.
- doi: 10.3802/jgo.2024.35.e45
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines... -
- CITED
-
- Close
- SHARE
-
- Close
- Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression
-
Kitadai R, Nishikawa T, Yoshida H, Mizoguchi C, Yamamoto K, Kato T, Yonemori K
- KMID: 2564871
- J Gynecol Oncol.
- 2024 Mar;35(2):e11.
- doi: 10.3802/jgo.2024.35.e11
Objective: This study aimed to evaluate mesothelin (MSLN) expression and determine its clinical significance and correlation with human epidermal growth factor receptor 2 (HER2) expression in gynecological carcinosarcoma. Methods: We retrospectively... -
- CITED
-
- Close
- SHARE
-
- Close
- Regularity of cervical cancer screening in Korea: analysis using national public data for 12 years
-
Kim JY, Hong J, Yoon J, Park J, Kim TH
- KMID: 2564877
- J Gynecol Oncol.
- 2024 Mar;35(2):e18.
- doi: 10.3802/jgo.2024.35.e18
Objective: To assess the frequency of regular uptake of national cervical cancer screening (CCS) program and identify associated factors among Korean women. Methods: This study is a fundamental investigation that employs... -
- CITED
-
- Close
- SHARE
-
- Close
- Evolving standards and future directions for systemic therapies in cervical cancer
-
Ang DJM, Chan JJ
- KMID: 2564887
- J Gynecol Oncol.
- 2024 Mar;35(2):e65.
- doi: 10.3802/jgo.2024.35.e65
Several groundbreaking clinical trials with the potential to transform the management paradigm of both locally advanced and persistent, recurrent, or metastatic cervical cancers have been presented in 2023. This review... -
- CITED
-
- Close
- SHARE
-
- Close
- Challenges and perspectives on less invasive surgery for early-stage cervical cancer: a critical analysis of the SHAPE trial and its implications
-
Takekuma M
- KMID: 2564885
- J Gynecol Oncol.
- 2024 Mar;35(2):e48.
- doi: 10.3802/jgo.2024.35.e48
-
- CITED
-
- Close
- SHARE
-
- Close
- Is it time to change surgery for early-stage low-risk cervical cancer to simple hysterectomy?
-
Park JY
- KMID: 2564884
- J Gynecol Oncol.
- 2024 Mar;35(2):e47.
- doi: 10.3802/jgo.2024.35.e47
-
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
-
Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, Kim BG, Wang PH, Chang TC, Yamamoto K, Han S, McKenzie J, Orlowski RJ, Miura T, Makker V, Kim YM
- KMID: 2564881
- J Gynecol Oncol.
- 2024 Mar;35(2):e40.
- doi: 10.3802/jgo.2024.35.e40
Objective: In the global phase 3 Study 309/KEYNOTE-775 (NCT03517449) at the first interim analysis, lenvatinib+pembrolizumab significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) versus treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Simple hysterectomy SHAPE-ing up to be the treatment of choice for early cervical cancer under 2 cm
-
Benseler A, Covens A
- KMID: 2564886
- J Gynecol Oncol.
- 2024 Mar;35(2):e49.
- doi: 10.3802/jgo.2024.35.e49
-
- CITED
-
- Close
- SHARE
-
- Close
- LncRNA linc01194 promotes the progress of endometrial carcinoma by up-regulating SOX2 through binding to IGF2BP1
-
Huang Z, Shen F, Chen J, Xie B, Chen X, Zhao Y, Chen S
- KMID: 2564880
- J Gynecol Oncol.
- 2024 Mar;35(2):e21.
- doi: 10.3802/jgo.2024.35.e21
Objective: Endometrial carcinoma (EC) is one of the most common gynecological malignant tumors. Our study showed that long non-coding RNA (lncRNA) linc01194 plays an important role in EC. We explored... -
- CITED
-
- Close
- SHARE
-
- Close
- Study of neoadjuvant chemotherapy in advanced malignant ovarian germ cell tumors at a tertiary center in western India
-
Vasanth A, Patel SM, Arora R, Parekh CD, Dave P, Patel BM, Vemanamandhi P
- KMID: 2564878
- J Gynecol Oncol.
- 2024 Mar;35(2):e19.
- doi: 10.3802/jgo.2024.35.e19
Objective: To study clinical characters and outcomes in patients of malignant ovarian germ cell tumor (MOGCT) undergoing surgery following neoadjuvant chemotherapy (NACT). Methods: Retrospective study of patients undergoing surgery following NACT... -
- CITED
-
- Close
- SHARE
-
- Close
- Robotic or laparoscopic pelvic exenteration for gynecological malignancies: feasible options to open surgery
-
Dudus L, Minciuna C, Tudor S, Lacatus M, Stefan B, Vasilescu C
- KMID: 2564872
- J Gynecol Oncol.
- 2024 Mar;35(2):e12.
- doi: 10.3802/jgo.2024.35.e12
Objective: To acknowledge that minimally invasive pelvic exenteration is a feasible alternative to open surgery and potentially identify prediction factors for patient outcome. Methods: The study was designed as a retrospective... -
- CITED
-
- Close
- SHARE
-
- Close
- Cervical screening among Chinese females in the era of HPV vaccination: a population-based survey on screening uptake and regular screening following an 18-year organized screening program
-
Choi HC, Leung K, Wu JT
- KMID: 2564879
- J Gynecol Oncol.
- 2024 Mar;35(2):e20.
- doi: 10.3802/jgo.2024.35.e20
Objective: China has a substantial disease burden of cervical cancer. To further understand preventive measures for reducing cervical cancer in China, this study aimed to correlate screening attendance and regular... -
- CITED
-
- Close
- SHARE
-
- Close
- A machine learning-based prediction model of pelvic lymph node metastasis in women with early-stage cervical cancer
-
Monthatip K, Boonnag M, Muangmool T, Charoenkwan K
- KMID: 2564876
- J Gynecol Oncol.
- 2024 Mar;35(2):e17.
- doi: 10.3802/jgo.2024.35.e17
Objective: To develop a novel machine learning-based preoperative prediction model for pelvic lymph node metastasis (PLNM) in early-stage cervical cancer by combining the clinical findings and preoperative computerized tomography (CT)... -
- CITED
-
- Close
- SHARE
-
- Close
- Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/ SIRT6 axis
-
Wang H, Li Y, Wang Y, Shang X, Yan Z, Li S, Bao W
- KMID: 2564873
- J Gynecol Oncol.
- 2024 Mar;35(2):e13.
- doi: 10.3802/jgo.2024.35.e13
Objective: We previously elucidated that long non-coding RNA Promoter of CDKN1A Antisense DNA damage Activated RNA (PANDAR) as a p53-dependent oncogene to promote cisplatin resistance in ovarian cancer (OC). Intriguingly,... -
- CITED
-
- Close
- SHARE
-
- Close
- Adjuvant carboplatin and paclitaxel with “sandwich” method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a singleinstitution
-
Chinnadurai A, Breadner D, Baloush Z, Lohmann AE, Black M, D’Souza D, Welch S
- KMID: 2564875
- J Gynecol Oncol.
- 2024 Mar;35(2):e16.
- doi: 10.3802/jgo.2024.35.e16
Objective: To evaluate disease-free survival (DFS) and overall survival (OS) associated with adjuvant carboplatin and paclitaxel chemotherapy interposed with radiation for advanced endometrial cancer. Methods: This is a cohort study of... -
- CITED
-
- Close
- SHARE
-
- Close
- Feasibility of laparoscopic VisceralPeritoneal Debulking (L-VPD) in patients with stage III–IV ovarian cancer: the ULTRA-LAP trial pilot study
-
Tozzi R, Noventa M, Saccardi C, Spagnol G, Tommasi OD, Coldebella D, Marchetti M
- KMID: 2564874
- J Gynecol Oncol.
- 2024 Mar;35(2):e14.
- doi: 10.3802/jgo.2024.35.e14
Objective: A non-randomized prospective clinical trial (ULTRA-LAP) was registered to test safety, side effects and efficacy of laparoscopic Visceral-Peritoneal Debulking (L-VPD) in patients with stage III–IV ovarian cancer (OC). A... -
- CITED
-
- Close
- SHARE
-
- Close
